Detection of LIM domain only 2 (LMO2) in normal human tissues and haematopoietic and non-haematopoietic tumours using a newly developed rabbit monoclonal antibody

Claudio Agostinelli, Jennifer C. Paterson, Rajeev Gupta, Simona Righi, Federica Sandri, Pier P. Piccaluga, Francesco Bacci, Elena Sabattini, Stefano A. Pileri, Teresa Marafioti

Research output: Contribution to journalArticle

22 Citations (Scopus)

Abstract

Aims: We describe a new rabbit monoclonal antibody, raised against a fixation-resistant epitope of the transcription regulator LIM domain only 2 (LMO2). Methods and results: Lymphoma cell lines and a large series of normal and neoplastic samples were investigated by Western blot and immunohistochemistry. The antibody detected nuclear positivity for the protein, with the exception of a proportion of classical Hodgkin lymphomas (HLs), peripheral T cell lymphomas (PTCLs) and solid tumours that showed granular cytoplasmic staining. In normal lympho-haematopoietic tissues, LMO2 was expressed at different intensities by CD34 + blasts, haematopoietic precursors, germinal centre (GC), mantle and splenic marginal zone B cells. While reactive with only scattered elements in the thymus and nine of 237 PTCLs, the antibody stained 31 of 39 T-acute lymphoblastic lymphoma/leukaemias (T-ALLs) and the T-ALL-derived human leukaemic cell line, CCRF-CEM. LMO2 was found in 88% of B-acute lymphoblastic lymphoma/leukaemias (B-ALLs), 5% chronic lymphocytic leukaemias (CLLs) and 14%, 57% and 41% of mantle, follicular and Burkitt lymphomas, respectively. In the setting of diffuse large B cell lymphomas (DLBCLs), LMO2-positivity was related strongly to a GC phenotype. LMO2 was found in 83% primary mediastinal large B cell lymphomas (PMBLs) and 100% nodular lymphocyte predominant Hodgkin lymphomas (NLPHLs), whereas only 10% of classical HLs were stained. Acute and chronic myeloid leukaemias were usually positive. Conclusions: The new anti-LMO2 antibody can be applied confidently to routine sections, contributing to the differential diagnosis of several lymphoma subtypes, subtyping of DLBCLs and potential development of innovative therapies.

Original languageEnglish
Pages (from-to)33-46
Number of pages14
JournalHistopathology
Volume61
Issue number1
DOIs
Publication statusPublished - Jul 2012

Fingerprint

Precursor Cell Lymphoblastic Leukemia-Lymphoma
Monoclonal Antibodies
Rabbits
Hodgkin Disease
Peripheral T-Cell Lymphoma
Neoplasms
Germinal Center
Lymphoma, Large B-Cell, Diffuse
Antibodies
Lymphoma
Cell Line
Investigational Therapies
Follicular Lymphoma
Burkitt Lymphoma
B-Cell Lymphoma
B-Cell Chronic Lymphocytic Leukemia
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Nuclear Proteins
Acute Myeloid Leukemia
Thymus Gland

Keywords

  • Immunohistochemistry
  • Leukaemia
  • LMO2
  • Lymphoma
  • Rabbit monoclonal antibody
  • Solid tumour

ASJC Scopus subject areas

  • Histology
  • Pathology and Forensic Medicine

Cite this

Detection of LIM domain only 2 (LMO2) in normal human tissues and haematopoietic and non-haematopoietic tumours using a newly developed rabbit monoclonal antibody. / Agostinelli, Claudio; Paterson, Jennifer C.; Gupta, Rajeev; Righi, Simona; Sandri, Federica; Piccaluga, Pier P.; Bacci, Francesco; Sabattini, Elena; Pileri, Stefano A.; Marafioti, Teresa.

In: Histopathology, Vol. 61, No. 1, 07.2012, p. 33-46.

Research output: Contribution to journalArticle

Agostinelli, Claudio ; Paterson, Jennifer C. ; Gupta, Rajeev ; Righi, Simona ; Sandri, Federica ; Piccaluga, Pier P. ; Bacci, Francesco ; Sabattini, Elena ; Pileri, Stefano A. ; Marafioti, Teresa. / Detection of LIM domain only 2 (LMO2) in normal human tissues and haematopoietic and non-haematopoietic tumours using a newly developed rabbit monoclonal antibody. In: Histopathology. 2012 ; Vol. 61, No. 1. pp. 33-46.
@article{eb0a8e7fd6ba4f3ea1c3d7b40e0b9e76,
title = "Detection of LIM domain only 2 (LMO2) in normal human tissues and haematopoietic and non-haematopoietic tumours using a newly developed rabbit monoclonal antibody",
abstract = "Aims: We describe a new rabbit monoclonal antibody, raised against a fixation-resistant epitope of the transcription regulator LIM domain only 2 (LMO2). Methods and results: Lymphoma cell lines and a large series of normal and neoplastic samples were investigated by Western blot and immunohistochemistry. The antibody detected nuclear positivity for the protein, with the exception of a proportion of classical Hodgkin lymphomas (HLs), peripheral T cell lymphomas (PTCLs) and solid tumours that showed granular cytoplasmic staining. In normal lympho-haematopoietic tissues, LMO2 was expressed at different intensities by CD34 + blasts, haematopoietic precursors, germinal centre (GC), mantle and splenic marginal zone B cells. While reactive with only scattered elements in the thymus and nine of 237 PTCLs, the antibody stained 31 of 39 T-acute lymphoblastic lymphoma/leukaemias (T-ALLs) and the T-ALL-derived human leukaemic cell line, CCRF-CEM. LMO2 was found in 88{\%} of B-acute lymphoblastic lymphoma/leukaemias (B-ALLs), 5{\%} chronic lymphocytic leukaemias (CLLs) and 14{\%}, 57{\%} and 41{\%} of mantle, follicular and Burkitt lymphomas, respectively. In the setting of diffuse large B cell lymphomas (DLBCLs), LMO2-positivity was related strongly to a GC phenotype. LMO2 was found in 83{\%} primary mediastinal large B cell lymphomas (PMBLs) and 100{\%} nodular lymphocyte predominant Hodgkin lymphomas (NLPHLs), whereas only 10{\%} of classical HLs were stained. Acute and chronic myeloid leukaemias were usually positive. Conclusions: The new anti-LMO2 antibody can be applied confidently to routine sections, contributing to the differential diagnosis of several lymphoma subtypes, subtyping of DLBCLs and potential development of innovative therapies.",
keywords = "Immunohistochemistry, Leukaemia, LMO2, Lymphoma, Rabbit monoclonal antibody, Solid tumour",
author = "Claudio Agostinelli and Paterson, {Jennifer C.} and Rajeev Gupta and Simona Righi and Federica Sandri and Piccaluga, {Pier P.} and Francesco Bacci and Elena Sabattini and Pileri, {Stefano A.} and Teresa Marafioti",
year = "2012",
month = "7",
doi = "10.1111/j.1365-2559.2012.04198.x",
language = "English",
volume = "61",
pages = "33--46",
journal = "Histopathology",
issn = "0309-0167",
publisher = "Wiley-Blackwell",
number = "1",

}

TY - JOUR

T1 - Detection of LIM domain only 2 (LMO2) in normal human tissues and haematopoietic and non-haematopoietic tumours using a newly developed rabbit monoclonal antibody

AU - Agostinelli, Claudio

AU - Paterson, Jennifer C.

AU - Gupta, Rajeev

AU - Righi, Simona

AU - Sandri, Federica

AU - Piccaluga, Pier P.

AU - Bacci, Francesco

AU - Sabattini, Elena

AU - Pileri, Stefano A.

AU - Marafioti, Teresa

PY - 2012/7

Y1 - 2012/7

N2 - Aims: We describe a new rabbit monoclonal antibody, raised against a fixation-resistant epitope of the transcription regulator LIM domain only 2 (LMO2). Methods and results: Lymphoma cell lines and a large series of normal and neoplastic samples were investigated by Western blot and immunohistochemistry. The antibody detected nuclear positivity for the protein, with the exception of a proportion of classical Hodgkin lymphomas (HLs), peripheral T cell lymphomas (PTCLs) and solid tumours that showed granular cytoplasmic staining. In normal lympho-haematopoietic tissues, LMO2 was expressed at different intensities by CD34 + blasts, haematopoietic precursors, germinal centre (GC), mantle and splenic marginal zone B cells. While reactive with only scattered elements in the thymus and nine of 237 PTCLs, the antibody stained 31 of 39 T-acute lymphoblastic lymphoma/leukaemias (T-ALLs) and the T-ALL-derived human leukaemic cell line, CCRF-CEM. LMO2 was found in 88% of B-acute lymphoblastic lymphoma/leukaemias (B-ALLs), 5% chronic lymphocytic leukaemias (CLLs) and 14%, 57% and 41% of mantle, follicular and Burkitt lymphomas, respectively. In the setting of diffuse large B cell lymphomas (DLBCLs), LMO2-positivity was related strongly to a GC phenotype. LMO2 was found in 83% primary mediastinal large B cell lymphomas (PMBLs) and 100% nodular lymphocyte predominant Hodgkin lymphomas (NLPHLs), whereas only 10% of classical HLs were stained. Acute and chronic myeloid leukaemias were usually positive. Conclusions: The new anti-LMO2 antibody can be applied confidently to routine sections, contributing to the differential diagnosis of several lymphoma subtypes, subtyping of DLBCLs and potential development of innovative therapies.

AB - Aims: We describe a new rabbit monoclonal antibody, raised against a fixation-resistant epitope of the transcription regulator LIM domain only 2 (LMO2). Methods and results: Lymphoma cell lines and a large series of normal and neoplastic samples were investigated by Western blot and immunohistochemistry. The antibody detected nuclear positivity for the protein, with the exception of a proportion of classical Hodgkin lymphomas (HLs), peripheral T cell lymphomas (PTCLs) and solid tumours that showed granular cytoplasmic staining. In normal lympho-haematopoietic tissues, LMO2 was expressed at different intensities by CD34 + blasts, haematopoietic precursors, germinal centre (GC), mantle and splenic marginal zone B cells. While reactive with only scattered elements in the thymus and nine of 237 PTCLs, the antibody stained 31 of 39 T-acute lymphoblastic lymphoma/leukaemias (T-ALLs) and the T-ALL-derived human leukaemic cell line, CCRF-CEM. LMO2 was found in 88% of B-acute lymphoblastic lymphoma/leukaemias (B-ALLs), 5% chronic lymphocytic leukaemias (CLLs) and 14%, 57% and 41% of mantle, follicular and Burkitt lymphomas, respectively. In the setting of diffuse large B cell lymphomas (DLBCLs), LMO2-positivity was related strongly to a GC phenotype. LMO2 was found in 83% primary mediastinal large B cell lymphomas (PMBLs) and 100% nodular lymphocyte predominant Hodgkin lymphomas (NLPHLs), whereas only 10% of classical HLs were stained. Acute and chronic myeloid leukaemias were usually positive. Conclusions: The new anti-LMO2 antibody can be applied confidently to routine sections, contributing to the differential diagnosis of several lymphoma subtypes, subtyping of DLBCLs and potential development of innovative therapies.

KW - Immunohistochemistry

KW - Leukaemia

KW - LMO2

KW - Lymphoma

KW - Rabbit monoclonal antibody

KW - Solid tumour

UR - http://www.scopus.com/inward/record.url?scp=84862868650&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84862868650&partnerID=8YFLogxK

U2 - 10.1111/j.1365-2559.2012.04198.x

DO - 10.1111/j.1365-2559.2012.04198.x

M3 - Article

C2 - 22394247

AN - SCOPUS:84862868650

VL - 61

SP - 33

EP - 46

JO - Histopathology

JF - Histopathology

SN - 0309-0167

IS - 1

ER -